Re Agreement

Fulcrum Pharma PLC
7 February 2002


For Immediate Release:                        07.00, Thursday, 7th February 2002



                         FULCRUM PHARMA DEVELOPMENTS LTD

            EXTENDS DEVELOPMENT AGREEMENT WITH XENOVA GROUP PLC

Hemel Hempstead, UK - Fulcrum Pharma plc (LSE: FUL), the independent drug
development company, announced today that it has successfully completed the
first milestone of its multi-year agreement with Xenova Group plc (LSE: XEN;
Nasdaq: XNVA) thus enabling clinical trials of their next generation oncology
product to commence. The next milestone target is to take the product through to
proof of concept.

Dr Jon Court, Fulcrum's Chief Executive Officer, welcomed this extension of the
relationship, saying:

'This is a significant contract for Fulcrum and we are delighted to continue our
relationship with Xenova following the successful completion of the preclinical
evaluation and technical development of XR11576. Fulcrum has delivered
regulatory, Ethics and hospital board approval, to initiate the first clinical
trial of Xenova's next-generation oncology product, XR11576, thus enabling human
studies to begin. This was achieved on budget. Our next goal is to provide the
infrastructure and expertise necessary to move this new product rapidly through
to proof of concept in the clinic.'


                                    - ENDS -

For further information, please contact :


Fulcrum Pharma plc
Jon Court, Chief Executive                                       0700 392 1103
Neil Oughton, Director Business Development                      0700 392 1105

Buchanan Communications                                          0207 466 5000
Nicola How / Louise Bolton

Xenova Group plc                                                 01753 706600
Hilary Reid-Evans



Notes to Editors:

Fulcrum Pharma plc is an independent, drug development company that is the first
to offer global virtual drug development and strategic outsourcing services to
the pharmaceutical industry.

The Company has expertise in the design, execution and delivery of drug
development programmes and relies on state of the art information technology and
infrastructure in the supply of its services.

Through Fulcrum's services to its clients, the Directors believe that there is
the capacity to deliver products faster and more efficiently to the global
pharmaceutical market. Fulcrum does this by using its skills in the design of
drug programmes that deliver the necessary information for decision-making and
product registration. In so doing, Fulcrum works closely with its clients to
meet their strategic R&D goals.

Fulcrum Pharma is listed on the Alternative Investment Market of the London
Stock Exchange.



                      This information is provided by RNS
            The company news service from the London Stock Exchange